Mandhair, Harpreet K. http://orcid.org/0000-0001-8753-7078
Radpour, Ramin
Westerhuis, Mira
Banz, Yara
Humbert, Magali http://orcid.org/0000-0003-3820-0297
Arambasic, Miroslav
Dengjel, Jörn
Davies, Andrew
Tschan, Mario P. http://orcid.org/0000-0001-5897-3647
Novak, Urban
Article History
Received: 8 June 2023
Revised: 4 January 2024
Accepted: 8 January 2024
First Online: 23 January 2024
Competing interests
: Andrew Davies: <i>Celgene (a Bristol Myers Squibb company):</i> Honoraria, Membership on an entity’s Board of Directors or advisory committees, Other: Travel to scientific conferences, Research Funding; <i>Roche:</i> Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees, Other: Research support. Travel to scientific conferences, Research Funding; <i>Kite, a Gilead company:</i> Honoraria, Membership on an entity’s Board of Directors or advisory committees, Other: Research support; <i>GSK:</i> Other: Research support; <i>Ascerta Pharma/Astra Zeneca:</i> Honoraria, Other: Research support; <i>Incyte:</i> Membership on an entity’s Board of Directors or advisory committees; <i>Abbvie:</i> Membership on an entity’s Board of Directors or advisory committees; <i>Takeda:</i> Honoraria, Membership on an entity’s Board of Directors or advisory committees, Other: Research support. Urban Novak: reports consulting fees and advisory board participation to/through the institution from and with Janssen-Cilag, Celgene (BMS), Takeda, AstraZeneca, Roche, Novartis, Incyte, Beigene, Kyowa Kirin, Gilead, Pierre Fabre and Miltenyi, payment of honoraria to the institution form Celgene (BMS), Novartis, Takeda, and Gilead, and meeting and/or travel support to the institution from Janssen, Roche, Gilead, and Takeda. The remaining authors declare no competing financial interests.